Clinical indicators used by practitioners to diagnose group A streptococcal throat infection: findings from two double-blind, randomised, placebo-controlled, multi-centre trials
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Poster
- By: SHEPHARD, Adrian (Reckitt Benckiser Healthcare International Ltd, Slough, Berkshire, United Kingdom)
- Co-author(s): Smith, Gary (Reckitt Benckiser Healthcare International Ltd, Slough, Berkshire, United Kingdom)
Aspley, Sue (Reckitt Benckiser Healthcare International Ltd, Slough, berkshire, United Kingdom)
Schachtel, Bernard (Yale University School of Medicine, New Haven, CT, United States of America)
Group A streptococcus (Strep A) is the most common bacterial cause of sore throat that may warrant antibiotics. Diagnosis based on clinical features alone is difficult. Recent trials have demonstrated the efficacy of flurbiprofen 8.75 mg lozenge for streptococcal and non-streptococcal pharyngitis. In these trials, practitioners used The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.